For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Forma Therapeutics, Inc.

USPTO Granted Patents = 125

% Expired Patents = 20.0

CIPO Patents = 3

EPO Patents = 27

Trademarks = 3

Forward Citations = 1,195

Loading Chart...

Loading Chart...

87 inventors (with patents filed for the assignee):

David R Lancia, Jr (76 out of 113 patents)

Matthew W Martin (50 out of 74 patents)

Xiaozhang Zheng (43 out of 113 patents)

4. David S Millan (38 out of 47 patents)

5. Bingsong Han (35 out of 76 patents)

6. Pui Yee Ng (35 out of 79 patents)

7. Aleksandra Rudnitskaya (34 out of 53 patents)

8. Kenneth W Bair (33 out of 82 patents)

9. Cuixian Liu (31 out of 56 patents)

10. Ann-Marie Campbell (31 out of 59 patents)

11. Jennifer R Thomason (30 out of 46 patents)

12. Mary-Margaret Zablocki (30 out of 48 patents)

13. Wei Lu (29 out of 39 patents)

14. Anna M Ericsson (29 out of 58 patents)

15. Gary Gustafson (28 out of 44 patents)

Core Competencies:

Mutant Isocitrate Dehydrogenase

CREB Binding Protein

Ubiquitin-Specific Protease

Bromodomain Inhibitors

Fatty Acid Synthase

Pyruvate Kinase Activators

HDAC Inhibitors

Quinolinone Derivatives

125 patents: Sort by Forward Citations

1. 12454532 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) binding protein (CBP) (2025-10-28),

2. 12378242 - Inhibiting CREB binding protein (CBP) (2025-08-05),

3. 12351577 - Inhibiting cyclic AMP-responsive element-binding protein (CREB) (2025-07-08),

4. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

5. 12053463 - Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile (2024-08-06),

6. 12049466 - Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors (2024-07-30),

7. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors (2024-07-23),

8. 11963956 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2024-04-23),

9. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2023-11-14),

10. 11801243 - Bromodomain inhibitors for androgen receptor-driven cancers (2023-10-31),

11. 11795168 - Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) (2023-10-24),

12. 11787803 - Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors (2023-10-17),

13. 11738018 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2023-08-29),

14. 11723905 - Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile (2023-08-15),

15. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2023-05-16),

Company Overview

Forma Therapeutics, Inc., based in Watertown, MA, specializes in developing innovative cancer therapeutics. The company focuses on targeting specific molecular pathways associated with cancer, utilizing advanced technologies such as mutant isocitrate dehydrogenase inhibitors and bromodomain inhibitors. Their research encompasses a range of core technology topics, including CREB binding protein, ubiquitin-specific proteases, and fatty acid synthase, aiming to create effective treatments that address unmet medical needs in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

125 Patents

#3 in Watertown, MA

#169 in Massachusetts

#3,099 in US

#6,403 in the World

Watertown, MA, United States of America

Forma Therapeutics, Inc.

Forward Citations = 1,195

87 inventors:

David R Lancia, Jr (76 out of 113 patents)

Matthew W Martin (50 out of 74 patents)

Xiaozhang Zheng (43 out of 113 patents)

4. David S Millan (38 out of 47 patents)

5. Bingsong Han (35 out of 76 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Forma Therapeutics, Inc.. Retrieved from https://idiyas.com/company/forma-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…